Concord Biotech Ltd

Concord Biotech Ltd share price headed higher 5.52% to Rs 1378.35 after the company's net profit surged by 20.57% to Rs 69.57 crore, while revenue from operations gained significantly 20.03% to Rs 309.07 crore in Q3FY26 over Q2FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 27.44 lakh crore, easing 4.06%. It has marginally improved by 3.17% over last one week and dipped slightly by 0.26% in last one month while the market capitalization of Concord Biotech Ltd has inched up 8.72% and 3.39% in the same period respectively. Profit before tax (PBT) of Concord Biotech Ltd stood at Rs 95.48 crore in Q3 FY26, climbing 11.44% year-on-year, and jumping 21.88% quarter-on-quarter. EBITDA came in at Rs 94 crore, rallying 25.38% YoY and surging by 35.46% sequentially. Total expenses increased by 15.45% to Rs 223.07 crore in Q3FY26 over Q3FY25. During the quarter, cost of materials consumed stood at Rs 63.66 crore, marginally falling by 8.86% YoY, while employee benefits expense was at Rs 52.31 crore, surging 19.87% YoY. For the TTM ended FY26, revenue from operations contracted by 12.10% to Rs 1054.89 crore, while net profit tanked by 30.25% to Rs 259.23 crore, compared to previous TTM. EBITDA witnessed a strong improvement of 48097% to Rs 315.04 crore, and PBT tumbled by 30.31% to Rs 344.65 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 266.88 crore in FY26, as against Rs 244.52 crore in FY25. Concord Biotech Ltd retreated by 5.49% in last one year, significantly outperforming the benchmark BSE Sensex which has declined by 13.19% during the same period.

Concord Biotech Ltd share price advanced by 5.52% to Rs 1378.35 after the company's net profit surged by 20.57% to Rs 69.57 crore, while revenue from operations gained significantly 20.03% to Rs 309.07 crore in Q3FY26 over Q2FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 27.54 lakh crore, gaining 3.36%. It has inched up 2.52% over last one week and dipped slightly by 0.63% in last one month while the market capitalization of Concord Biotech Ltd has marginally improved by 7.44% and 3.63% in the same period respectively. Profit before tax (PBT) of Concord Biotech Ltd stood at Rs 95.48 crore in Q3 FY26, climbing 11.44% year-on-year, and expanding by 21.88% quarter-on-quarter. EBITDA came in at Rs 94 crore, jumping 25.38% YoY and surging by 35.46% sequentially. Total expenses increased by 15.45% to Rs 223.07 crore in Q3FY26 over Q3FY25. During the quarter, cost of materials consumed stood at Rs 63.66 crore, slightly declining by 8.86% YoY, while employee benefits expense was at Rs 52.31 crore, witnessing a strong rise of 19.87% YoY. For the TTM ended FY26, revenue from operations fell 12.10% to Rs 1054.89 crore, while net profit tumbled by 30.25% to Rs 259.23 crore, compared to previous TTM. EBITDA soared by 48097% to Rs 315.04 crore, and PBT collapsed by 30.31% to Rs 344.65 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 266.88 crore in FY26, as against Rs 244.52 crore in FY25. Concord Biotech Ltd plunged by 10.43% in last one year, outperforming the benchmark BSE Sensex which has declined by 13.18% during the same period.

Concord Biotech Limited has fixed Wednesday, November 04, 2026, as the record date for the issuance of bonus equity shares in a 1:1 ratio, according to a regulatory filing on October 27, 2026. The deemed date of allotment for the bonus equity shares will be Thursday, November 05, 2026, as per SEBI regulations.

Concord Biotech Limited will hold a board meeting on Tuesday, October 27, 2026, to consider and approve the unaudited standalone and consolidated financial results for the second quarter and half year ended September 30, 2026, along with a limited review report from its statutory auditors. The trading window for the company's securities will remain closed for 48 hours after the declaration of the financial results, as previously communicated in a letter dated September 28, 2026.

Concord Biotech Limited submitted a certificate to the National Stock Exchange of India Limited and BSE Limited on October 7, 2026, detailing compliance with Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended September 30, 2026. The certificate, dated October 3, 2026, was issued by MUFG Intime India Private Limited, the company's registrar and share transfer agent, confirming the handling of securities received for dematerialization and their subsequent listing on stock exchanges.

Concord Biotech Limited will close its trading window for equity shares from October 1, 2026, until 48 hours after the declaration of the unaudited financial results for the quarter and half year ended September 30, 2026, in compliance with the SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company’s code of conduct.

Concord Biotech Limited will hold a board meeting on Wednesday, September 23, 2026, to consider a proposal for the declaration of bonus equity shares to existing shareholders, subject to shareholder approval. Trading window for designated persons and their immediate relatives will be closed from September 19, 2026, until September 26, 2026, in accordance with Securities and Exchange Board of India regulations.

Concord Biotech Ltd share price ticked higher by 0.23% to Rs 1333.2. The Company's net profit plunged by 34.78% to Rs 57.7 crore, while revenue from operations nosedived 21.03% to Rs 257.49 crore in Q2FY26 over Q1FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 23.86 lakh crore, easing 6%. It has marginally improved by 2.79% over last one week and spiked sharply by 15.59% in last one month while the market capitalization of Concord Biotech Ltd has gained 13.75% and 24.57% in the same period respectively. Profit before tax (PBT) of Concord Biotech Ltd stood at Rs 78.34 crore in Q2 FY26, jumping 33.39% year-on-year, and plunging by 31.33% quarter-on-quarter. EBITDA came in at Rs 70 crore, rallying 45.75% YoY and nosediving by 32.59% sequentially. Total expenses fell by 14.92% to Rs 193.21 crore in Q2FY26 over Q2FY25. During the quarter, cost of materials consumed stood at Rs 69.85 crore, slightly declining by 0.98% YoY, while employee benefits expense was at Rs 43.64 crore, dropping 8.65% YoY. For the TTM ended FY26, revenue from operations fell 12.10% to Rs 1054.89 crore, while net profit tanked by 30.25% to Rs 259.23 crore, compared to previous TTM. EBITDA jumped by 48097% to Rs 315.04 crore, and PBT collapsed by 30.31% to Rs 344.65 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 266.88 crore in FY26, as against Rs 244.52 crore in FY25. Concord Biotech Ltd crashed 26.39% in last one year, underperforming the benchmark BSE Sensex which has slipped by 4.36% during the same period.

Concord Biotech will hold a meeting of the Board of Directors of the Company on 31 July 2026.

Concord Biotech announced that the 41th Annual General Meeting(AGM) of the company will be held on 31 July 2026.